239 related articles for article (PubMed ID: 24648773)
1. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
Davidson BA; Secord AA
Int J Womens Health; 2014; 6():289-300. PubMed ID: 24648773
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
4. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
8. Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.
Mahner S; Woelber L; Mueller V; Witzel I; Prieske K; Grimm D; Keller-V Amsberg G; Trillsch F
Front Oncol; 2015; 5():211. PubMed ID: 26500886
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.
Khosravi-Shahi P; Cabezon-Gutierrez L
Anticancer Agents Med Chem; 2012 Oct; 12(8):982-7. PubMed ID: 22263801
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
14. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Joly F; Fabbro M; Berton D; Lequesne J; Anota A; Puszkiel A; Floquet A; Vegas H; Bourgeois H; Bengrine Lefevre L; You B; Pommeret F; Lortholary A; Spaeth D; Hardy-Bessard AC; Abdeddaim C; Kaminsky-Forrett MC; Tod M; Kurtz JE; Del Piano F; Meunier J; Raban N; Alexandre J; Mouret-Reynier MA; Ray-Coquard I; Provansal Gross M; Brachet PE
Gynecol Oncol; 2022 Sep; 166(3):389-396. PubMed ID: 35902297
[TBL] [Abstract][Full Text] [Related]
17. Where do antiangiogenic agents belong in the treatment algorithm for ovarian cancer?
Dizon DS
Am J Clin Oncol; 2013 Oct; 36(5):519-25. PubMed ID: 21552100
[TBL] [Abstract][Full Text] [Related]
18. New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.
Cowey CL; Sonpavde G; Hutson TE
Onco Targets Ther; 2010 Oct; 3():147-55. PubMed ID: 21049083
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]